MednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Neurosurgery

TTFields   

Questions discussed in this category


Is it reasonable to extrapolate data from Glioblastoma and discuss Tumor Treating Fields in patients with Grade 4, IDH Mutant, astrocytomas?
2 Answers available

How do you sequence TTFields into your salvage therapy plan for patients with recurrent glioblastoma?
3 Answers available

What is the role for TTFields in patients who cannot undergo complete surgical resection for glioblastoma?
2 Answers available

Are there particular subgroups of patients with glioblastoma who derive the most benefit from TTFields?
5 Answers available
17929623860246017


Papers discussed in this category


JAMA, 2017-12-19
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Frontiers in oncology, 2020 Jul 28
Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma.

Oncology letters, 2019 Nov 19
Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields.

Annals of translational medicine, 2021 Dec
Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma.

Related Topics in Neurosurgery

  • Lung Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Palliation
  • Neuro-Oncology
  • Melanoma/Skin Cancer
  • Non-malignant Disease
  • Pediatric Hematology/Oncology
  • Sarcoma

Copyright © 2026 Mednet
All Rights Reserved.